Shares of AVITA Medical, Inc. (RCEL) slipped over 35% on Wednesday morning after the regenerative medicine company cut its forecast.
RCEL is currently trading at $8.94, down $5.12 or 36.43%, on the Nasdaq. The stock opened its trading at $10.27 after closing Tuesday at $14.06. The stock has traded between $7.51 and $18.93 in the past 52-week period.
For the quarter ended December 31, 2024, AVITA Medical now expects commercial revenue to be about $18.4 million, reflecting growth of around 30% over the same period in 2023. Previously, the company expected revenues of $22.3 million to $24.3 million.
The company expects full-year 2024 commercial revenue to be around $64.3 million, reflecting growth of about 29% over the full year 2023. Previously, the company expected revenues of $68.0 million to $70.0 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.